Clinical trials: Acute Circulatory Failure
Severe Sepsis, Cardiac Arrest
Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes
A hospitals manual method of patient monitoring will be implemented in an automated system and supported by an early patient deterioration detection for timely escalation.
- Conditions
- Severe Sepsis, Cardiac Arrest, Respiratory Failure
- Trial name
- NCT01692847
- Where
- United Kingdom
- Volunteers
- 678 people
- Sponsor
- Philips Healthcare
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Acute Myocardial Infarction, Congestive Heart Failure
IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction
The primary objective is to evaluate the safety and effectiveness of the IK-5001 device for the prevention of ventricular remodeling and congestive heart failure when administered to subjects who had successful percutaneous…
- Conditions
- Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
- Trial name
- PRESERVATION-1 (NCT01226563)
- Testing
- IK-5001, Saline Solution
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 303 people
- Sponsor
- Bellerophon BCM LLC
Acute Heart Failure
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following…
- Trial name
- PIONEER-HF (NCT02554890)
- Testing
- sacubitril/valsartan (LCZ696), Enalapril
- Where
- 123 sites in United States
- Volunteers
- 887 people
- Sponsor
- Novartis Pharmaceuticals
Acute Decompensated Heart Failure, Acute Heart Failure
SVC Occlusion in Subjects With Acute Decompensated Heart Failure
Safety and performance evaluation of the preCARDIA System for patients with ADHF.
- Conditions
- Acute Decompensated Heart Failure, Acute Heart Failure, Congestive Heart Failure, Heart Diseases
- Trial name
- VENUS-HF (NCT03836079)
- Testing
- preCARDIA system
- Where
- 17 sites in United States
- Volunteers
- 60 people
- Sponsor
- Abiomed Inc.
Heart Failure, ADHF
Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions
Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease…
- Conditions
- Heart Failure, ADHF, Acute MI
- Trial name
- COMPASSION (NCT04905160)
- Testing
- COMPASSION Digital Biomarker
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Aventyn, Inc.
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
Acute Heart Failure
Heart & Diabetes - Feasibility Study
The main purpose of this study is to validate an intensive protocol of insulin infusion and subsequent subcutaneous insulin administration with the support of continuous glucose monitoring, in addition to reference finger-stick…
- Trial name
- NCT00922402
- Testing
- Intensive insulin infusion
- Where
- 2 sites in Italy
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Renal Failure, Acute Kidney Injury
A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)
This is a Phase 1, randomized, double-blind, dose escalation, safety and pharmacokinetic study. The study will be conducted in approximately 10 sites in the United States.
- Trial name
- NCT00683553
- Testing
- I5NP
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Quark Pharmaceuticals
Heart Failure, Acute Coronary Syndromes
A Cut-off Value Study of N-terminal Brain Natriuretic Peptide （Chemiluminescence Method）
The aim of the study is to evaluate diagnostic performance of N-terminal Brain natriuretic Peptide (NT-proBNP) in acute heart failure among Chinese population.
- Trial name
- NT-proBNP，HF (NCT06691477)
- Testing
- No Interventions
- Where
- 4 sites in China
- Volunteers
- 1,104 people, healthy volunteers welcome
- Sponsor
- Beckman Coulter, Inc.
Heart Failure, Acute Myocardial Infarction
Carvedilol Vascular Efficacy Trial
Beta-blockers should be administered to all patients with heart failure stages II to IV NYHA. It should also be administered to patients with stage I after myocardial infarction.
- Trial name
- CARVEDIA (NCT01484327)
- Testing
- Carvedilol
- Where
- Greece
- Volunteers
- 415 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hyponatremia
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation
The purpose of this study is to determine the safety and efficacy of lixivaptan in the treatment of hyponatremia in patients with congestive heart failure.
- Trial name
- NCT00578695
- Testing
- lixivaptan
- Where
- 287 sites in United States, Argentina and 13 more
- Volunteers
- 652 people
- Sponsor
- CardioKine Inc.
Injury of Kidney, Acute Renal Failure
A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery
This is a Phase 1, randomized, double-blind, dose escalation, safety and pharmacokinetic study. The study will be conducted in approximately 8-10 centers in the United States and Switzerland.
- Trial name
- NCT00554359
- Testing
- I5NP (a small interfering RNA)
- Where
- 11 sites in United States, Israel and 1 more
- Volunteers
- 16 people
- Sponsor
- Quark Pharmaceuticals
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system…
- Trial name
- NEUTRALIZE-CRS (NCT03836482)
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SeaStar Medical
Cardiogenic Shock
CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial
Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%.
- Trial name
- Corvad AMICS (NCT06886113)
- Testing
- Conventional circulatory support, CorVad
- Where
- China
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
Dyspnea, Hypertension
Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF
The purpose of this study is to evaluate dyspnea improvement and other parameters of efficacy and safety in acute heart failure (AHF) patients receiving an intravenous (IV) infusion of clevidipine in comparison to standard of…
- Conditions
- Dyspnea, Hypertension, Acute Heart Failure
- Trial name
- PRONTO II (NCT04592380)
- Testing
- Stage 1: Clevidipine (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
- Where
- 9 sites in United States
- Sponsor
- The Medicines Company
Heart Failure, Congestive
An Exploratory Study of Nesiritide in Participants With Acute Heart Failure
The purpose of this exploratory study is to assess the efficacy and safety of nesiritide in participants with acute (a quick and severe form of illness in its early stage) heart failure (when the heart inadequately pumps blood…
- Trial name
- NCT00490724
- Testing
- Nesiritide (1+0.01), Nesiritide (2+0.005), Nesritide (2+0.01)
- Where
- 11 sites in Japan
- Volunteers
- 67 people
- Sponsor
- Janssen Pharmaceutical K.K.
Heart Failure, Congestive
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
- Trial name
- RELAX-AHF (NCT00520806)
- Testing
- Relaxin
- Where
- 3 sites in United States, Israel
- Volunteers
- 1,161 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies